Protein tyrosine kinase-7 (PTK7), a member of receptor tyrosine kinase superfamily initially identified as colon carcinoma kinase-4 (CCK-4), is highly expressed in various human malignancies (1, 2) . Encoding fragments of PTK7 were initially identified in mRNA from human melanocytes, and, subsequently PTK7 was fully cloned from a colon cancer tissue (3, 4) . The protein consists of seven immunoglobulin-like extracellular domains, a single transmembrane domain, and cytoplasmic domain with tyrosine kinase homology that lacks vital catalytic activity but maintains signal transduction (4-7).
Deletion of the PTK7 gene in mice is lethal, and the embryos developed many defects in the gastrulating cell process. Subsequently, it was found that the protein PTK7 is conserved through evolution and plays a pivotal role in cell movement and localization during embryonic development (5, (7) (8) (9) . Endogenous ligands of PTK7 have not yet been identified.
As indicated above, PTK7 was cloned from colon cancer, although not expressed in normal colon. Further research showed that it is also expressed by other cancers including gastric, acute myeloid leukemia (AML), lung and glioblastoma overexpressing CD44 (6, (10) (11) (12) (13) (14) .
The role of PTK7 in cancer is controversial, perhaps because it might play different roles in the biology of cancers that arise from different tissues. Interestingly, while in some cancers PTK7 is upregulated and believed to promote tube formation, migration, angiogenesis and invasiveness of endothelial cells (8) , PTK7 is found to be downregulated in other cancers and/or during advanced stages of the cancer (15) (16) (17) (18) . Moreover, in lung squamous cell carcinoma it was suggested to be a tumor suppressor, and when it was transfected into lung cancer cell lines it reduced cell proliferation, invasion, and migration (18) . Hence, PTK7 may be a pharmaceutical target in some cancers; however, its role in each specific targeted cancer requires exploration.
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One of the limitations in studying PTK7 is the absence of a method for evaluating and quantifying the expression of PTK7 protein in cancer tissue non-invasively over time. Currently there is no radioactive tracer that will allow such studies. To address this need, we developed a positron emission tomography (PET) tracer that targets PTK7, based on a known aptamer sequence named Sgc8 (19, 20) .
Aptamers are short single-stranded DNA or RNA oligonucleotides that possess high selectivity and specificity to a target molecule. The specific binding of aptamers to their targets depends on a distinctive and unique three dimensional folding, and they display high affinities that are similar to antibodies. In contrast to antibodies, the relatively small molecular weight of aptamers allows rapid penetration into tissues and fast clearance from the blood to give higher target-to-background ratio at early time points. Therefore, aptamers are attractive candidates for in vivo PET imaging (21, 22) .
Sgc8 aptamer contains 41 oligonucleotides and was selected by cell based systematic evolution of ligands by exponential enrichment (SELEX) against human T lymphoblast CCRF-CEM cells (19, 20) . The target of the Sgc8 aptamer was deduced as PTK7 using biotin-Sgc8 and magnetic streptavidin beads for isolation of biomarker complexes and LC-MS/MS to identify the complexed protein. Here we describe radiolabeling of Sgc8 with the PET isotope F-18 via a click chemistry reaction and evaluation of 18 F-Tr-Sgc8 ex vivo and in vivo for stability and ability to image and quantify PTK7 expression in different mouse tumor models.
MATERIALS AND METHODS

General
Supplemental materials describe the procedures for radiolabeling of 
Statistical Analysis
Results were presented as mean ± standard deviation (SD). Group comparisons were made using Student's t test for unpaired data. P values <0.05 were considered statistically significant.
RESULTS
Chemistry and Radiochemistry
Sgc8 aptamer, consisting of 41 oligonucleotides, was modified at the 5' with a terminal hexynyl group (Figure 1) . Conjugation of unlabeled Sgc8-alkyne to 1.5 equivalent of fluorobenzyl azide in the presence of excess amount of CuSO4·5H2O and sodium ascorbate resulted in full conversion into the desired product (Supplemental Figure 1) which was verified by LC-MS analysis (Supplemental Figure S2) . The automated radiochemical synthesis of 18 Ffluorobenzyl azide was achieved using an aromatic fluoride substitution on a novel spirocyclic hypervalent iodine(III) precursor (23) (1, Figure 1 ). The labeling yield was 32 ± 3% (n = 5), nondecay-corrected (ndc) based on F-18 activity. Table S1 ).
Reaction of Sgc8-alkyne with 18 F-fluorobenzyl azide was conducted as described for the unlabeled fluorobenzyl azide, and similarly, resulted in formation of one major and desired product. The high SA 18 F-fluorobenzyl azide was all consumed (Supplemental Figure S3) .
Typically, 150 µg (11 nmol) of Sgc8-alkyne were used for radiolabeling. Attempts to minimize the amount of the aptamer to 50 µg (3.8 nmol) per reaction resulted in the same conversion (Supplemental Material Table S1 ). However, using 13 µg (1 nmol) of aptamer, resulted in only 48% conversion into the desired labeled aptamer ( Table 1 ). The crude reaction was purified on NAP5 column to give (n=5) based on initial 18 F-fluorobenzyl azide radioactivity. The final specific activity of the labeled aptamer, calculated by dividing the obtained radioactivity by the total mass of Sgc8-alkyne used for the reaction, was 182-198 mCi/µmol (6.7-7.3 GBq/µmol).
Biology
PTK7 Expression by HCT116 and U87MG Cells
Flow cytometry and Western blot analysis showed higher expression by HCT116 than by U87MG cells (Figures 2A and 2B) . 18 F-Tr-Sgc8 binding affinity to HCT116 was slightly better (2.7 ± 0.6 nM, n = 2) than U87MG (16.9 ± 2.1 nM, n = 2, Figure 2C ). The amount of 18 F-TrSgc8 captured on each cell line also correlated with expression levels of PTK7 ( Figure 2C ).
Western blot analysis of proteins from tumor lysates showed that HCT116 retained PKT7 expression in vivo, while the protein level was almost undetected in U87MG tumor lysate ( Figure 2D ).
PTK7 Imaging in Tumor-Bearing Mice
18
F-Tr-Sgc8 uptakes at all the time points examined were significantly higher in HCT116 than those in U87MG xenografts (0.76 ± 0.09 vs. 0.13 ± 0.06 %ID/g at 30 min p.i. and 0.54 ± 0.12 vs. 0.19 ± 0.06 %ID/g at 1 h p.i., Figures 3A and B) . 
Ex Vivo and In Vivo Stability of 18 F-Tr-Sgc8
18 F-Tr-Sgc8 stability was initially evaluated ex vivo in mouse serum. An aliquot of the serum was taken at 30 min and 1 h post-incubation and the radioactivity was diluted using saline.
The aptamer readily bound to serum components and, thus, most of the radioactivity remained in the pellet. Denaturation of the proteins at 95 °C increased aptamer recovery, but remained low with 80% of proteins. Gel electrophoretic analysis showed that no significant amount of metabolites was formed in the serum up to 1 h incubation ( Figure 5A ). Activity extracted from 30 min time-point was injected into HPLC (Supplemental Figure S5A) ; no degradation of the labeled aptamer was observed. 18 F-Tr-Sgc8 stability was further evaluated in vivo in the blood and urine. Since Figure   S5C ). It is important to emphasize that traces of unlabeled aptamer could be detected in the urine samples, according to the UV chromatogram (Supplemental Figure S5C ).
Discussion
PTK7 expression was shown to have controversial roles in different tumors, and it seems to be dependent on several conditions, which are in part tissue specific. Hence, the study of clinical significance and function of PTK7 in cancers is an on-going research effort. However, it is at least partially hampered by the lack of a reliable method to evaluate PTK7 expression noninvasively in whole tumors (12, 24) . An example of the above mentioned controversy is a study done in adenocarcinoma patients that suggests that PTK7 expression predicts a favorable prognosis (13) . On the other hand, evaluation of AML patients showed that PTK7-positive patients had higher resistance to anthracycline-based cancer chemotherapy and had a significantly reduced rate of relapse-free survival (25) . The methods for determination of PTK7 expression by tumors and tumor cells are limited to immunohistochemistry and PCR, which are conducted on biopsy samples. A method to evaluate the receptor expression in the whole tumor non-invasively could be a great asset to study the significance and functions for PTK7 in a wide variety of cancers. In this study we address this unmet need through the development of a PET tracer for PTK7 based on a DNA aptamer.
We have previously published the labeling of Tenascin-C aptamer with F-18 via Nsuccinimidyl 4- Table S1 ), which is obviously better than 18 F-SFB conjugation yields realized for Tenascin C aptamer. Our preliminary in vivo PET studies showed suboptimal images when a small mass of aptamer was injected into the mice, whereas, higher mass amounts resulted in better images (Supplemental Figure S6) . This may be due to the very rapid clearance of the radioactive aptamer through gallbladder and kidneys. We believe that an increase in injected mass slowed the clearance and/or metabolism just enough to allow higher uptake in target tissues. Indeed our optimized conditions used 11 nmol of Sgc8-alkyne and purification of radiolabeled product from unreacted precursor was not necessary. This phenomenon of lower uptake in gallbladder coupled with higher uptake in the target organ/tumor might be beneficial to other tracers. However, our experience is limited to this aptamer, and further studies on this phenomenon should be carried out with other tracers. If this phenomenon is seen with other tracers, then tracer development studies should also include experiments to optimize the unlabeled-to-labeled tracer ratio, in order to circumvent gallbladder accumulation and improve target uptake. In our standard radiolabeling method, 18 F-Tr-Sgc8 was injected with 5-8 µg of unreacted Sgc8-alkyne per mouse.
PET studies showed specific accumulation of 18 F-Tr-Sgc8 in HCT116 tumor-bearing mice ( Figures 3A and 3C ) that express high level of PTK7 ( Figure 2D ). U87MG tumors express lower level of PTK7 ( Figure 2D ) and had relatively lower uptake of Figure S4 and Supplemental Movie S1). The uptake in the intestine, which was higher than that in the tumor, suggests that F-Tr-Sgc8 had considerable uptake in the intestine ( Figure 3C ) and by on October 29, 2017. For personal use only. jnm.snmjournals.org Downloaded from also showed some bone uptake (0.37 ± 0.06 %ID/g), which suggests metabolic de-fluorination ( Figure 3C ) or, perhaps, formation of F-18 clicked phosphate metabolite which accumulates in the bone. When Sgc8 was labeled with 18 F-SFB, the bone uptake was much lower (0.11±0.02
%ID/g at 1 h p.i. (Supplemental Figure S7) . A more detailed study of the effect of different chemical linkers on de-fluorination may be required. 18 F-Tr-Sgc8 stability was further tested in vitro in mouse serum and in vivo in blood and urine. 18 F-Tr-Sgc8 proved to be stable in mouse serum with no significant metabolite formation ( Figure 5A ). About 25-30% of the total injected radioactivity was collected from the urine at 30 min p.i., which indicated a fast clearance of 18 F-Tr-Sgc8 through kidneys. Radio-HPLC showed two small molecule based components but no parent 18 F-Tr-Sgc8. These products were probably caused by the metabolism of the phosphodiester bond between the aptamer and/or the prosthetic group (Supplemental Figure S5C) . Typically large molecules such as aptamers or proteins are eluted in fraction 4 (0.75 -1.0 mL); however, we observed most of the radioactivity remained on the column and could only elute with extensive washing. This is indicative of small molecules.
One would be an alcohol that is consistent with the more hydrophobic peak seen in HPLC at 24.9 min (Supplemental Figure S5C) ; and the other would contain a phosphate group and peaked at 15.4 min (Supplemental Figure S5C) . Upon analysis by LC-MS, we observed not only unreacted Sgc8 but also one large molecule with a deconvoluted mass of 18 kDa, which is 6 kDa higher than the unreacted Sgc8 (Supplemental Figure S8) . This supports our hypothesis that the aptamer or its fragments bind to some blood component (lipids/small proteins) in vivo.
It is important to note that although we observed some degradation of the 
